Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma

Medical Oncology

Volumn 26, Issue 1, 2009, Pages 67-72

  Meazza, C ^a   Casanova, M ^a   Zaffignani, E ^a   Luksch, R ^a   Podda, M ^a   Favini, F ^a   Catania, S ^a   Biassoni, V ^a   Morosi, C ^a   Ferrari, A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Doxorubicin; New agent; Rhabdomyosarcoma; Topotecan; Vincristine

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER RELAPSE; CANCER SURGERY; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG EFFICACY; FEMALE; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT CANCER; RHABDOMYOSARCOMA; SCHOOL CHILD; THROMBOCYTOPENIA; TREATMENT RESPONSE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASM RECURRENCE, LOCAL; RHABDOMYOSARCOMA; TOPOTECAN; TREATMENT OUTCOME; VINCRISTINE;

EID: 65549144421     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9085-8     Document Type: Article

References (22)

1. Gurney JG, Young JL, Roffers SD. Soft tissue sarcomas. In: Gloecker LA, Smith MA, editors. SEER pediatric monograph cancer incidence and survival among children and adolescents: United States SEER program 1975-1995. Bethesda, MD: National Cancer Institute; 1999. p. 111-24.
2. W Crist 1995 The third Intergroup Rhabdomyosarcoma Study J Clin Oncol 13 610 30
3. S Baker 1988 Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from Intergroup Rhabdomyosarcoma Study IV J Clin Oncol 6 308 14
4. C Stewart W Zamboni W Crom P Houghton 1996 Topoisomerase I interactive drugs in children with cancer Invest New Drugs 14 37 47 10.1007/BF00173681
5. National Cancer Institute. NCI common toxicity criteria, version 1. Investigator's handbook: a manual of participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment, National Cancer Institute. Bethesda, MD: U.S. Department of Health and Human Services, Public Heath Service, National Institute of Health; 1993.
6. J Thompson C Stewart P Houghton 1998 Animal models for studying the action of topoisomerase-I target drugs Biochim Biophys Acta 1400 301 19
7. PJ Houghton 1992 Evaluation of 9-dimethyminomethyl-10hydroxycamptothecin against xenografts derived from adult and childhood solid tumors Cancer Chemother Pharmacol 31 229 39 10.1007/BF00685553
8. K Rewinky J Verweij 1998 Review of Phase I clinical studies with topotecan Semin Oncol 24 3 20
9. DG Tubergen 1996 Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) of topotecan using a five-days course in children with refractory solid tumors: a Pediatric Oncology Group Study J Pediatr Hematol Oncol 18 352 61 10.1097/00043426-199611000-00004 (Pubitemid 26359251)
10. R Nitschke 1998 Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study J Ped Hematol Oncol 20 315 8 10.1097/00043426-199807000-00006 (Pubitemid 28483337)
11. AS Pappo 2001 Up-front window trial of topotecan in previously untreated children and adolescents with matastatic rhabdomyosarcoma: an Intergroup Rhabdomyosarcoma Study J Clin Oncol 19 213 9
12. RL Saylors 2001 Pediatric oncology group: cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors. A Pediatric Oncology Group Phase II Study J Clin Oncol 19 3463 9
13. DO Walterhouse 2004 Efficacy of topotecan and cyclophosphamide given in Phase II window trial in children with newly diagnosed matastatic rhabdomyosarcoma: a Children's Oncology Group Study J Clin Oncol 22 1398 403 10.1200/JCO.2004.05.184 (Pubitemid 41103621)
14. JJ Lager 2006 Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group J Clin Oncol 24 3415 22 10.1200/JCO.2005.01.9497 (Pubitemid 46638898)
15. Breitfeld PP. Analysis of the therapeutic first-line Phase II window trials in rhabdomyosarcoma. Educational Book, American Society of Clinical Oncology Annual Meeting, Chicago, 2007; p. 607-10.
16. Arndt CA, et al. Randomized phase III trial comparing vincristine, actinomycin, cyclophosphamide (VAC) with VAC/V topotecan/cyclophosphamide (TC) for intermediate risk rhabdomyosarcoma (IRRMS). D9803, COG Study. Proc Am Soc Clin Oncol. 2007;25(188) (abstract 9509).
17. A Garaventa 2003 A phase II Study of topotecan with vincristine and doxorubicine in children with recurrent/refractory neuroblastoma Cancer 98 2488 94 10.1002/cncr.11797 (Pubitemid 37466665)
18. Rowinsky EK, Kaufmann SH. Topotecan in combination chemiotheraphy. Semin Oncol. 1997;24:S20-11-S20-26.
19. R Kim 1992 Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice Int J Cancer 50 760 6 10.1002/ijc.2910500516
20. J Thompson 1999 Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts Clin Cancer Res 5 3617 31
21. MF Cheung S Chatterjee NA Berger 1994 Schedule-depend cytotoxicity of topotecan alone and in combination chemotherapy regimens Oncol Res 6 269 79
22. E Jonsson H Fridborg P Nygren 1998 Synergistic interactions of combination of topotecan with standard drugs in primary cultures of human tumor cells from patients Eur J Clin Pharmacol 54 509 14 10.1007/s002280050505 (Pubitemid 28487370)